MallInckrodt Plc (MNK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
November 2018
157
About the Report
About the Report
Summary
Mallinckrodt Plc (Mallinckrodt) is develops, produces, commercializes, and distributes specialty pharmaceutical therapies and products. The company offers both branded and specialty generics for autoimmune and rare diseases in the specialty therapeutic areas of rheumatology, nephrology, neurology, pulmonology and ophthalmology. It also offers analgesics and gastrointestinal products and immunotherapy and neonatal respiratory critical care therapies; active pharmaceutical ingredients (APIs) and external manufacturing services. The company sells its products either directly or through distributors to retail pharmacies, institutions and various end users. It has subsidiaries in Prince Edward Island, Ireland, Bermuda, Germany, Australia, Canada, Maryland, Delaware, Massachusetts, the UK, California, Netherlands, Alberta, Switzerland, and Luxembourg. Mallinckrodt is headquartered in Surrey, the UK.
MallInckrodt Plc (MNK)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
MallInckrodt Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deal Details 18
Asset Purchase 18
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 18
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 20
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 21
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 23
Venture Financing 24
InfaCare Pharma Raises USD3.5 Million in Venture Financing 24
Infacare Pharma Raises USD5.5 Million in Venture Financing 25
Vtesse Raises USD17 Million in Extended Series A Financing 26
Vtesse Raises USD25 Million in Series A Financing 27
Infacare Pharma Raises USD1.3 Million in Venture Financing 28
Athyrium Opportunities Invests in Ikaria 29
Ocera Therapeutics Raises USD 20 Million In Venture Financing 30
Infacare Pharma Raises USD 3.6 Million In First Tranche Of Series C Financing 31
Ocera Therapeutics Raises USD 1.5 Million In Venture Financing 33
Partnerships 35
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 35
Mallinckrodt Enters into Research Partnership with Washington University 36
Mesoblast Enters into Agreement with Mallinckrodt Pharma 37
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 38
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 39
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 40
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 41
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 42
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 43
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 44
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 45
Merger 46
Ocera Therapeutics And Tranzyme Pharma Complete Merger 46
Licensing Agreements 48
Sucampo Exercises Option for Licensing Agreement with Cancer Prevention Pharma 48
Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 49
BioVectra Enters into Licensing Agreement with TUBE Pharmaceuticals 50
West Pharma Enters into Licensing Agreement with Mallinckrodt 51
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 52
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 53
Sucampo Pharma Enters into Licensing Agreement with Harbin Gloria Pharma 54
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 55
Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 56
Lyric Pharma Enters into Licensing Agreement with Ocera Therapeutics 58
Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 59
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 60
Equity Offering 61
Sucampo Pharma Plans to Raise Funds through Public Offering of shares 61
Ocera Therapeutics Raises Funds through Private Placement of Shares 62
Ocera Therapeutics Raises USD25.5 Million in Public Offering of Shares 63
Vtesse Spin Out from Cydan Development 64
Ocera Therapeutics Raises USD25.2 Million in Public Offering of Shares 65
Ocera Therapeutics Completes Private Placement Of Units For USD 28 Million 67
Sucampo Pharma Files Registration Statement For Public Offering Of Securities For USD 150 Million 69
Debt Offering 70
Sucampo Pharma Raises USD300 Million in Private Placement of 3.25% Notes Due 2021 70
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 71
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 72
Asset Transactions 73
Baxter International Acquires Two Hemostat and Sealant Products from Mallinckrodt 73
Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 74
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 75
Numab Acquires ND003 From Sucampo 77
Acquisition 78
Mallinckrodt Acquires Sucampo Pharma for USD1.2 Billion 78
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 80
Mallinckrodt Acquires InfaCare Pharma 82
Sucampo Pharma Acquires Vtesse for USD200 Million 83
Mallinckrodt Acquires Stratatech 84
Sucampo Pharma Acquires R-Tech Ueno for USD274.5 Million in Tender Offer 85
Mallinckrodt Pharma Acquires Therakos from Gores Group 87
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 89
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 91
Mallinckrodt Completes Acquisition Of Cadence Pharma For USD 1.4 Billion In Tender Offer 93
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For USD 101 Million 95
Mallinckrodt Completes Acquisition Of CNS Therapeutics For USD 100 Million 96
MallInckrodt Plc-Key Competitors 98
MallInckrodt Plc-Key Employees 99
MallInckrodt Plc-Locations And Subsidiaries 100
Head Office 100
Other Locations & Subsidiaries 100
Recent Developments 104
Strategy And Business Planning 104
Oct 16, 2017: Mallinckrodt Opens Specialty Brands Office In New Jersey, Announces USD 100,000 Donation To Princeton University Program For High Achieving, Low-Income High School Students 104
May 15, 2017: Mallinckrodt Opens New Global Centre for Medical Device R&D 105
Financial Announcements 106
Aug 07, 2018: Mallinckrodt reports second quarter 2018 results and raises guidance for 2018 106
May 08, 2018: Mallinckrodt Reports First Quarter 2018 Results 108
Feb 27, 2018: Mallinckrodt Reports Fourth Quarter and Fiscal 2017 Results, Announces 2018 Guidance and Sets 2018 Strategic Priorities 110
Nov 07, 2017: Mallinckrodt Reports Earnings Results for Third Quarter of Fiscal 2017 112
Aug 08, 2017: Mallinckrodt Reports Earnings Results for Second Quarter of Fiscal 2017 114
May 08, 2017: Mallinckrodt Reports Earnings Results for First Quarter of Fiscal 2017 116
Feb 07, 2017: Mallinckrodt Reports Transition Period Results and Announces 2017 Guidance 118
Corporate Communications 120
Oct 01, 2018: Mallinckrodt responds to CBS' 60 minutes segment 120
Jun 21, 2018: Mallinckrodt Launches Scientific Advisory Council 121
Apr 04, 2018: Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018 122
Apr 04, 2018: Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors 123
Sep 20, 2017: Mallinckrodt Announces Election Of David Norton To Its Board Of Directors 124
May 19, 2017: Mallinckrodt Donates GBP100,000 to Ashford and St. Peter's Hospitals NHS Foundation Trust to Support Neonatal Care 125
Jan 04, 2017: Karen Sheehy to Succeed Raymond Furey as Chief Compliance Officer of Mallinckrodt 126
Legal and Regulatory 127
Sep 22, 2017: Mallinckrodt Advocates for Comprehensive, Multi-Prong Action Plan to Fight Opioid Abuse and Misuse in the United States 127
Aug 04, 2017: Mallinckrodt Statement On Lawsuit Filed By Multnomah County, Oregon, Related To Opioid Products 128
Aug 02, 2017: Mallinckrodt Statement on U.S. DOJ Subpoena Related to Opioid Products 129
Government and Public Interest 130
Aug 06, 2018: Mallinckrodt boosts rare-disease research at Washington University 130
Product News 131
08/10/2017: Study Results Published in The Lancet Demonstrate Safety and Efficacy of Intrathecal VTS-270 in Niemann-Pick Disease Type C1 131
07/17/2017: NIH scientists find rare disease clues in cell's recycling system 132
06/01/2017: Ocera Initiates Phase 2a Study with Oral OCR-002 in Patients with Cirrhosis 133
05/26/2017: Ocera Therapeutics to Host KOL Conference Call on Hepatic Encephalopathy and Other Complications of Liver Disease 134
04/18/2017: New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1 135
03/15/2017: Vtesse Completes Enrollment of Phase 2b/3 Pivotal Clinical Trial of VTS-270 in Niemann-Pick Type C1 Disease 136
Clinical Trials 137
Feb 14, 2018: Mallinckrodt Enrolls First Patient in Phase 1 Study of ExpressGraft C9T1 Skin Tissue 137
Oct 20, 2017: Ocera Presents Three Posters and an Oral Presentation on OCR-002 at the AASLD Liver Meeting 138
Sep 28, 2017: Sucampo Pharmaceuticals Announces FDA Acceptance of sNDA for AMITIZA in Children with Pediatric Functional Constipation, with Priority Review Designation 140
Aug 23, 2017: Ocera Therapeutics Selected to Present an Oral Presentation and Three Posters on OCR-002 at the AASLD Liver Meeting 2017 141
Apr 12, 2017: Ocera Therapeutics Announces Presentation of Data Showing OCR-002 Prevented Progression of Fibrosis in Preclinical Model of Non-alcoholic Fatty Liver Disease 142
Mar 08, 2017: Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy 143
Jan 30, 2017: Ocera Announces Top-line Results for Phase 2b Study in Hepatic Encephalopathy 144
Jan 05, 2017: Ocera Announces Successful Phase 1 Clinical Study of Orally-Administered OCR-002 in Patients with Cirrhosis 145
Other Significant Developments 146
Aug 09, 2018: New Mallinckrodt data analysis shows limited use of opioid-free analgesia, underutilization in some patients more prone to opioid-related adverse events 146
Aug 01, 2018: Mallinckrodt initiates proof-of-concept study of nitric oxide gas in ex-vivo system of human lung transplants 147
Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters 148
Aug 30, 2017: Mallinckrodt Statement on Missouri Attorney General Investigation 150
Jul 27, 2017: Mallinckrodt Will Respond to Sen. McCaskill's Request for Information on Opioid Anti-Diversion and Suspicious Order Monitoring Activities 151
Jun 21, 2017: Mallinckrodt and Massachusetts Health & Hospital Association Announce Joint Initiative for Developing Pain Stewardship Programs Within Hospitals 152
Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims 153
Apr 03, 2017: Mallinckrodt Statement on DEA and USAOs Agreement in Principle 155
Jan 18, 2017: Mallinckrodt Responds to Media Reports Regarding Previously Disclosed FTC Investigation 156
Appendix 157
Methodology 157
About GlobalData 157
Contact Us 157
Disclaimer 157
List of Figure
List of Figures
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13
List of Table
List of Tables
MallInckrodt Plc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
MallInckrodt Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
MallInckrodt Plc, Deals By Therapy Area, 2012 to YTD 2018 11
MallInckrodt Plc, Medical Devices Deals, 2012 to YTD 2018 13
MallInckrodt Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Mallinckrodt Acquires Three Topical Hemostasis Drugs from Medicines Company 18
Biovectra to Acquire Manufacturing Facility from Sepracor Canada 20
Questcor Pharma Acquires Rights To Synacthen And Synacthen Depot 21
Mallinckrodt Completes Acquisition Of Rights To Roxicodone From Xanodyne Pharma 23
InfaCare Pharma Raises USD3.5 Million in Venture Financing 24
Infacare Pharma Raises USD5.5 Million in Venture Financing 25
Vtesse Raises USD17 Million in Extended Series A Financing 26
Vtesse Raises USD25 Million in Series A Financing 27
Infacare Pharma Raises USD1.3 Million in Venture Financing 28
Athyrium Opportunities Invests in Ikaria 29
Ocera Therapeutics Raises USD 20 Million In Venture Financing 30
Infacare Pharma Raises USD 3.6 Million In First Tranche Of Series C Financing 31
Ocera Therapeutics Raises USD 1.5 Million In Venture Financing 33
Questcor Pharma Enters Into Licensing Agreement With European Company To Develop Novel Melanocortin Peptides 35
Mallinckrodt Enters into Research Partnership with Washington University 36
Mesoblast Enters into Agreement with Mallinckrodt Pharma 37
Valeo Pharma Enters into Distribution Agreement with Questcor Pharma for Synacthen Depot 38
Vtesse Enters into Agreement with National Institutes of Health for VTS-270 39
INO Therapeutics Enters into Agreement with Lee's Pharma for Inomax 40
Mallinckrodt Pharma And Medtronic Enter Into Clinical Agreement For Intrathecal Therapeutics 41
Cadence Pharma Enters Into Development Agreement With Labs Grifols For Ofirmev Injection 42
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 43
Zogenix Enters Into Co-Promotion Agreement With Mallinckrodt For Sumavel DosePro 44
BioVectra Enters Into Co-Marketing Agreement With Quanta BioSciences 45
Ocera Therapeutics And Tranzyme Pharma Complete Merger 46
Sucampo Exercises Option for Licensing Agreement with Cancer Prevention Pharma 48
Sucampo Enters into Licensing Agreement with Cancer Prevention Pharma 49
BioVectra Enters into Licensing Agreement with TUBE Pharmaceuticals 50
West Pharma Enters into Licensing Agreement with Mallinckrodt 51
Intellipharmaceutics International Enters into Licensing Agreement with Mallinckrodt 52
Sucampo Pharma Enters into Option Agreement with Cancer Prevention Pharma 53
Sucampo Pharma Enters into Licensing Agreement with Harbin Gloria Pharma 54
Vtesse Enters into Licensing Agreement with National Institutes of Health for Cyclodextrins 55
Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 56
Lyric Pharma Enters into Licensing Agreement with Ocera Therapeutics 58
Ocera Therapeutics Enters Into Technology Transfer and License Agreement With F. Hoffmann-La Roche 59
Sucampo Pharma and R-Tech Ueno Enter into Licensing Agreement with Par Pharma 60
Sucampo Pharma Plans to Raise Funds through Public Offering of shares 61
Ocera Therapeutics Raises Funds through Private Placement of Shares 62
Ocera Therapeutics Raises USD25.5 Million in Public Offering of Shares 63
Vtesse Spin Out from Cydan Development 64
Ocera Therapeutics Raises USD25.2 Million in Public Offering of Shares 65
Ocera Therapeutics Completes Private Placement Of Units For USD 28 Million 67
Sucampo Pharma Files Registration Statement For Public Offering Of Securities For USD 150 Million 69
Sucampo Pharma Raises USD300 Million in Private Placement of 3.25% Notes Due 2021 70
Mallinckrodt to Raise USD750 Million in Private Placement of Notes Due 2023 71
Mallinckrodt to Raise up to USD1.2 Billion in Private Placement of Notes 72
Baxter International Acquires Two Hemostat and Sealant Products from Mallinckrodt 73
Aurobindo Pharma Denies Acquisition of Generic Drug Unit from Mallinckrodt 74
Piramal Enterprises Acquires Intrathecal Therapy Business from Mallinckrodt for 203 Million 75
Numab Acquires ND003 From Sucampo 77
Mallinckrodt Acquires Sucampo Pharma for USD1.2 Billion 78
Mallinckrodt Acquires Ocera Therapeutics for up to USD117 Million 80
Mallinckrodt Acquires InfaCare Pharma 82
Sucampo Pharma Acquires Vtesse for USD200 Million 83
Mallinckrodt Acquires Stratatech 84
Sucampo Pharma Acquires R-Tech Ueno for USD274.5 Million in Tender Offer 85
Mallinckrodt Pharma Acquires Therakos from Gores Group 87
Mallinckrodt Acquires Ikaria for up to USD2.3 Billion 89
Mallinckrodt Acquires Questcor Pharma for USD5.6 Billion 91
Mallinckrodt Completes Acquisition Of Cadence Pharma For USD 1.4 Billion In Tender Offer 93
Questcor Pharma Completes Acquisition Of BioVectra, Contract Manufacturing Company, For USD 101 Million 95
Mallinckrodt Completes Acquisition Of CNS Therapeutics For USD 100 Million 96
MallInckrodt Plc, Key Competitors 98
MallInckrodt Plc, Key Employees 99
MallInckrodt Plc, Other Locations 100
MallInckrodt Plc, Subsidiaries 100
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.